Please provide your email address to receive an email when new articles are posted on . Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) is an option after any intraocular surgery ...

The Conversation reports cataract surgery is safe and common, with over 90% achieving 20/20 vision, but patients need to ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...

Cataract surgery remains one of the most frequently performed and successful surgical procedures worldwide, involving the removal of a clouded natural lens and its replacement with an intraocular lens ...

The TECNIS Odyssey IOL addresses a significant unmet need for cataract patients seeking greater spectacle independence., Bizz ...

FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients ...

Q: What is the payment policy for an Astigmatism-Correcting Intraocular Lens (A-C-IOL) inserted following removal of a cataract in a hospital or ambulatory surgical center? CMS: The payment policy for ...